Characteristics at baseline of 266 patients with or without a flare of chronic hepatitis B
| Baseline | Flare (n = 67) | No Flare (n = 199) | p Value |
|---|---|---|---|
| *Mean (SD). | |||
| ALT, alanine aminotransferase; ULN, upper limit of normal; HBV, hepatitis B virus; IFN, interferon. | |||
| Age* | 34 (12) | 35 (13) | 0.804 |
| ALT* (×ULN) | 2.9 (1.4) | 4.8 (3.8) | <0.001 |
| Log HBV DNA* | 9.1 (1.1) | 9.1 (0.9) | 0.764 |
| Male (%) | 52 (78) | 153 (77) | 0.947 |
| Transmission (%) | 0.132 | ||
| Vertical | 18 (27) | 42 (21) | |
| (Homo)sexual | 7 (10) | 22 (11) | |
| Parenteral | 8 (12) | 21 (11) | |
| Transfusion | 4 (6) | 3 (2) | |
| Unknown | 30 (45) | 111 (56) | |
| Genotype (%) | 0.738 | ||
| A | 19 (28) | 71 (36) | |
| B | 7 (10) | 16 (8) | |
| C | 11 (16) | 28 (14) | |
| D | 26 (39) | 77 (39) | |
| Race (%) | 0.432 | ||
| Caucasian | 47 (70) | 149 (75) | |
| Asian | 13 (19) | 39 (20) | |
| Cirrhosis (%) | 10 (19) | 14 (7) | 0.060 |
| Previous lamivudine (%) | 8 (12) | 31 (16) | 0.459 |
| Previous IFN (%) | 12 (18) | 47 (24) | 0.311 |
| Monotherapy (%) | 32 (48) | 104 (52) | |
| Combination therapy (%) | 35 (52) | 95 (48) | 0.566 |